Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.76. Which is the better fit depends on your goals.
| ALNY | MSTU | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $106.80 |
52-Week Low | $278.09 | $1.46 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MSTU trades at $1.875, up 1.35% today, but the technical outlook is bearish with moving averages signaling strong selling pressure. The ETF, which aims for 2x daily returns of MicroStrategy (MSTR), has experienced extreme volatility and significant losses historically. Recent news highlights its high-risk nature, with articles noting substantial declines over the past year.
The outlook remains highly speculative due to leveraged exposure to MSTR's volatility. Key risks include daily rebalancing effects amplifying losses, dependence on MSTR's performance, and overall market sentiment toward Bitcoin-linked assets. This ETF is suitable only for investors comfortable with extreme risk and short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
